This column was originally published on RealMoney on Aug. 3 at 11:42 a.m. EDT. It's being republished as a bonus for readers.

Suddenly, we have to be selective in the slowdown stocks.


(HSY) - Get Report

catches a downgrade from Wachovia and it plummets back to $53.


(MDT) - Get Report

lowers guidance and you get smacked in

St. Jude


and in

Boston Scientific

(BSX) - Get Report

(that Guidant acquisition is looking more and more like a colossal mistake).

We can look at this two ways. One is to say that the trend into the soft goods and defensives has run its course. The other is to say we have simply become more selective and are no longer in the "bid everything up because we could catch too much disappointment" phase.

I am strictly betting on the latter. Why? Because why else will

Procter & Gamble

(PG) - Get Report

keep going up? That was the tell that this is an intra-rotation rotation and no more than that.

Watch the employment number tomorrow. Any strength and you are going to go right back to this group, but now the stocks matter. You can't throw darts anymore. Not even at the drugs, where


(PFE) - Get Report

suddenly has Lipitor issues, which look a lot like pre-Plavix issues that have dogged


(BMY) - Get Report

-- although I would still buy it because it is too cheap.

Don't lose heart in these stocks. We have three more months of outperformance, and five more months if the


tightens again after this one.

At the time of publication, Cramer was long Bristol-Myers.

Jim Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for

Action Alerts PLUS. Listen to Cramer's RealMoney Radio show on your computer; just click

here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click

here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click

here to get his second book, "You Got Screwed!" and click

here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by

clicking here. has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from